Literature DB >> 15516975

Dissection of transcriptional programmes in response to serum and c-Myc in a human B-cell line.

Isabel Schlosser1, Michael Hölzel, Reinhard Hoffmann, Helmut Burtscher, Franz Kohlhuber, Marino Schuhmacher, Rob Chapman, Ulrich H Weidle, Dirk Eick.   

Abstract

Proliferation of higher eukaryotic cells is triggered by the proto-oncogene c-myc (myc), which is induced downstream of a large number of growth factor receptors. Myc, a basic helix-loop-helix leucine zipper transcription factor, transmits growth signals by up- and downregulation of target genes. The importance of Myc in growth control is well established. However, the number of growth control genes requiring Myc as an essential factor for regulation after mitogenic stimulation of cells is not yet clear. Here, we have studied the transcriptional programme of a human B-cell line, P493-6, in response to Myc and serum. P493-6 cells do not express the endogenous myc, nor is it induced by serum stimulation. Proliferation of the cells is dependent upon both the expression of a tetracycline-regulated myc gene and serum stimulation. Using DNA microarrays, expression profiling was performed following stimulation of cells with serum, with Myc, or with both. We observed serum regulation of >1000 genes. A number of these genes were synergistically or antagonistically regulated by Myc. Moreover, we identified >300 Myc-regulated genes that were almost unresponsive to serum. Gene ontology analysis revealed that a high proportion of Myc target genes are involved in ribosome biogenesis and tRNA metabolism. The data support our current notion that Myc is essential for the regulation of a large number of growth-related genes in B cells, and cannot be replaced by other serum-induced factors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15516975     DOI: 10.1038/sj.onc.1208198

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  44 in total

Review 1.  Turning on a fuel switch of cancer: hnRNP proteins regulate alternative splicing of pyruvate kinase mRNA.

Authors:  Mo Chen; Jian Zhang; James L Manley
Journal:  Cancer Res       Date:  2010-10-26       Impact factor: 12.701

2.  Tumor metabolism: hnRNP proteins get in on the act.

Authors:  Mo Chen; Charles J David; James L Manley
Journal:  Cell Cycle       Date:  2010-05-15       Impact factor: 4.534

Review 3.  MYC and transcription elongation.

Authors:  Peter B Rahl; Richard A Young
Journal:  Cold Spring Harb Perspect Med       Date:  2014-01-01       Impact factor: 6.915

4.  BET bromodomain inhibition as a therapeutic strategy to target c-Myc.

Authors:  Jake E Delmore; Ghayas C Issa; Madeleine E Lemieux; Peter B Rahl; Junwei Shi; Hannah M Jacobs; Efstathios Kastritis; Timothy Gilpatrick; Ronald M Paranal; Jun Qi; Marta Chesi; Anna C Schinzel; Michael R McKeown; Timothy P Heffernan; Christopher R Vakoc; P Leif Bergsagel; Irene M Ghobrial; Paul G Richardson; Richard A Young; William C Hahn; Kenneth C Anderson; Andrew L Kung; James E Bradner; Constantine S Mitsiades
Journal:  Cell       Date:  2011-09-01       Impact factor: 41.582

5.  Molecular classification of MYC-driven B-cell lymphomas by targeted gene expression profiling of fixed biopsy specimens.

Authors:  Christopher D Carey; Daniel Gusenleitner; Bjoern Chapuy; Alexandra E Kovach; Michael J Kluk; Heather H Sun; Rachel E Crossland; Chris M Bacon; Vikki Rand; Paola Dal Cin; Long P Le; Donna Neuberg; Aliyah R Sohani; Margaret A Shipp; Stefano Monti; Scott J Rodig
Journal:  J Mol Diagn       Date:  2014-11-07       Impact factor: 5.568

6.  Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer.

Authors:  Takeshi Shimamura; Zhao Chen; Margaret Soucheray; Julian Carretero; Eiki Kikuchi; Jeremy H Tchaicha; Yandi Gao; Katherine A Cheng; Travis J Cohoon; Jun Qi; Esra Akbay; Alec C Kimmelman; Andrew L Kung; James E Bradner; Kwok-Kin Wong
Journal:  Clin Cancer Res       Date:  2013-09-17       Impact factor: 12.531

7.  HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer.

Authors:  Charles J David; Mo Chen; Marcela Assanah; Peter Canoll; James L Manley
Journal:  Nature       Date:  2009-12-13       Impact factor: 49.962

8.  Expression and clinical significance of PD-L1 and c-Myc in non-small cell lung cancer.

Authors:  Cuiling Zhou; Gang Che; Xiaobin Zheng; Junlan Qiu; Zhinan Xie; Yunyan Cong; Xiaofeng Pei; Hongyu Zhang; Huanhuan Sun; Haiqing Ma
Journal:  J Cancer Res Clin Oncol       Date:  2019-09-20       Impact factor: 4.553

9.  Enhancer invasion shapes MYCN-dependent transcriptional amplification in neuroblastoma.

Authors:  Rhamy Zeid; Matthew A Lawlor; Evon Poon; Jaime M Reyes; Mariateresa Fulciniti; Michael A Lopez; Thomas G Scott; Behnam Nabet; Michael A Erb; Georg E Winter; Zoe Jacobson; Donald R Polaski; Kristen L Karlin; Rachel A Hirsch; Nikhil P Munshi; Thomas F Westbrook; Louis Chesler; Charles Y Lin; James E Bradner
Journal:  Nat Genet       Date:  2018-01-29       Impact factor: 38.330

10.  A core MYC gene expression signature is prominent in basal-like breast cancer but only partially overlaps the core serum response.

Authors:  Sanjay Chandriani; Eirik Frengen; Victoria H Cowling; Sarah A Pendergrass; Charles M Perou; Michael L Whitfield; Michael D Cole
Journal:  PLoS One       Date:  2009-08-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.